No 'significant' benefit of favipiravir, umifenovir combination in Covid treatment: Glenmark

Glenmark had in May intimated the study to examine whether early administration of a combination of Favipiravir and Umifenovir enhances antiviral efficacy on Covid-19 patients. The company said that addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lrVGaY
via IFTTT